Valerie Vinette,Anthony Castro,Heather Kim,Carolina Trujillo,Min Xie,Martin Gengenbacher,Thomas R Ioerger,Sabine Ehrt
{"title":"Interstitial and recruited macrophages prevent tuberculosis relapse by limiting immune evasion.","authors":"Valerie Vinette,Anthony Castro,Heather Kim,Carolina Trujillo,Min Xie,Martin Gengenbacher,Thomas R Ioerger,Sabine Ehrt","doi":"10.1038/s44321-026-00432-6","DOIUrl":null,"url":null,"abstract":"Alveolar macrophages are the first immune cells to encounter Mycobacterium tuberculosis (Mtb) in the lungs, but they frequently fail to eliminate this pathogen, allowing Mtb to persist and replicate. Interstitial macrophages (IMs) are enlisted to restrict bacterial growth and limit immune evasion. While IMs have been implicated in controlling acute Mtb infection, their role during latent tuberculosis infection (LTBI) remains unexplored. To address this, we utilized a previously established mouse model of paucibacillary Mtb infection that recapitulates key aspects of human LTBI to deplete IMs during the latent phase. Depletion of IMs and recruited macrophages (RMs) led to TB relapse in 26% of mice compared to 2% in controls. Mice that relapsed exhibited an increased proportion of pro-inflammatory IMs and elevated concentrations of G-CSF, GM-CSF, IL-3, IL-12, IL-13, IL-17A, and KC in the lung. These findings demonstrate that IMs and RMs play a critical role in controlling latent Mtb and preventing TB relapse.","PeriodicalId":11597,"journal":{"name":"EMBO Molecular Medicine","volume":"21 1","pages":""},"PeriodicalIF":8.3000,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMBO Molecular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s44321-026-00432-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Alveolar macrophages are the first immune cells to encounter Mycobacterium tuberculosis (Mtb) in the lungs, but they frequently fail to eliminate this pathogen, allowing Mtb to persist and replicate. Interstitial macrophages (IMs) are enlisted to restrict bacterial growth and limit immune evasion. While IMs have been implicated in controlling acute Mtb infection, their role during latent tuberculosis infection (LTBI) remains unexplored. To address this, we utilized a previously established mouse model of paucibacillary Mtb infection that recapitulates key aspects of human LTBI to deplete IMs during the latent phase. Depletion of IMs and recruited macrophages (RMs) led to TB relapse in 26% of mice compared to 2% in controls. Mice that relapsed exhibited an increased proportion of pro-inflammatory IMs and elevated concentrations of G-CSF, GM-CSF, IL-3, IL-12, IL-13, IL-17A, and KC in the lung. These findings demonstrate that IMs and RMs play a critical role in controlling latent Mtb and preventing TB relapse.
期刊介绍:
EMBO Molecular Medicine is an open access journal in the field of experimental medicine, dedicated to science at the interface between clinical research and basic life sciences. In addition to human data, we welcome original studies performed in cells and/or animals provided they demonstrate human disease relevance.
To enhance and better specify our commitment to precision medicine, we have expanded the scope of EMM and call for contributions in the following fields:
Environmental health and medicine, in particular studies in the field of environmental medicine in its functional and mechanistic aspects (exposome studies, toxicology, biomarkers, modeling, and intervention).
Clinical studies and case reports - Human clinical studies providing decisive clues how to control a given disease (epidemiological, pathophysiological, therapeutic, and vaccine studies). Case reports supporting hypothesis-driven research on the disease.
Biomedical technologies - Studies that present innovative materials, tools, devices, and technologies with direct translational potential and applicability (imaging technologies, drug delivery systems, tissue engineering, and AI)